Jupiter Neurosciences, Inc.

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences is developing JOTROL™, a patented micellar delivery platform that enables resveratrol to effectively cross the blood-brain barrier, providing a safe oral treatment for Alzheimer’s disease and rare neurological disorders. This technology addresses neuroinflammation and oxidative stress, offering potential therapeutic benefits without gastrointestinal side effects.

```xml <problem> Current treatments for Alzheimer's disease and rare neurological disorders often fail to deliver sufficient levels of therapeutic agents to the brain due to the blood-brain barrier. Oral administration of some drugs can also lead to gastrointestinal side effects, limiting their tolerability and effectiveness. </problem> <solution> Jupiter Neurosciences is developing JOTROL™, a patented micellar delivery platform designed to enhance the bioavailability of resveratrol, enabling it to effectively cross the blood-brain barrier. This technology aims to provide a safe and orally administered treatment option for Alzheimer’s disease and rare neurological disorders. By utilizing a micellar formulation, JOTROL™ facilitates the absorption of resveratrol, allowing it to reach therapeutic levels in the central nervous system without causing gastrointestinal side effects. The enhanced delivery and activity of resveratrol address neuroinflammation and oxidative stress, offering potential therapeutic benefits for patients with limited treatment options. </solution> <features> - Patented micellar delivery platform for enhanced resveratrol bioavailability - Oral softgel formulation for convenient administration - Ability to effectively cross the blood-brain barrier - Reduced gastrointestinal side effects compared to traditional oral resveratrol - Anti-inflammatory and oxidative-stress-reducing mechanisms of action - Potential application in treating Alzheimer’s disease and rare neurological disorders </features> <target_audience> The primary target audience includes individuals suffering from Alzheimer’s disease and rare neurological disorders, as well as healthcare professionals seeking safer and more effective treatment options. </target_audience> ```

What does Jupiter Neurosciences, Inc. do?

Jupiter Neurosciences is developing JOTROL™, a patented micellar delivery platform that enables resveratrol to effectively cross the blood-brain barrier, providing a safe oral treatment for Alzheimer’s disease and rare neurological disorders. This technology addresses neuroinflammation and oxidative stress, offering potential therapeutic benefits without gastrointestinal side effects.

Employees
6 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

Jupiter Neurosciences, Inc.

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Jupiter Neurosciences is developing JOTROL™, a patented micellar delivery platform that enables resveratrol to effectively cross the blood-brain barrier, providing a safe oral treatment for Alzheimer’s disease and rare neurological disorders. This technology addresses neuroinflammation and oxidative stress, offering potential therapeutic benefits without gastrointestinal side effects.

Funding

No funding information available.

Team (5+)

No team information available.

Company Description

Problem

Current treatments for Alzheimer's disease and rare neurological disorders often fail to deliver sufficient levels of therapeutic agents to the brain due to the blood-brain barrier. Oral administration of some drugs can also lead to gastrointestinal side effects, limiting their tolerability and effectiveness.

Solution

Jupiter Neurosciences is developing JOTROL™, a patented micellar delivery platform designed to enhance the bioavailability of resveratrol, enabling it to effectively cross the blood-brain barrier. This technology aims to provide a safe and orally administered treatment option for Alzheimer’s disease and rare neurological disorders. By utilizing a micellar formulation, JOTROL™ facilitates the absorption of resveratrol, allowing it to reach therapeutic levels in the central nervous system without causing gastrointestinal side effects. The enhanced delivery and activity of resveratrol address neuroinflammation and oxidative stress, offering potential therapeutic benefits for patients with limited treatment options.

Features

Patented micellar delivery platform for enhanced resveratrol bioavailability

Oral softgel formulation for convenient administration

Ability to effectively cross the blood-brain barrier

Reduced gastrointestinal side effects compared to traditional oral resveratrol

Anti-inflammatory and oxidative-stress-reducing mechanisms of action

Potential application in treating Alzheimer’s disease and rare neurological disorders

Target Audience

The primary target audience includes individuals suffering from Alzheimer’s disease and rare neurological disorders, as well as healthcare professionals seeking safer and more effective treatment options.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.